{"count":12,"docs":"https://aiswingx.com/docs","items":[{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/RevenueFromContractWithCustomerExcludingAssessedTax","change":84.26273118824423,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Revenue","label_en":"Revenue","label_ko":"\ub9e4\ucd9c","period_type":"duration","xbrl_tag":"RevenueFromContractWithCustomerExcludingAssessedTax"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/RevenueFromContractWithCustomerExcludingAssessedTax","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-08-31","period_start":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-113","unit":"USD","value":673064000.0,"xbrl_fact_id":"f-113"},{"comparative":true,"instant":false,"period_end":"2025-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-114","unit":"USD","value":7894000.0,"xbrl_fact_id":"f-114"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Revenue of USD 673,064,000 for the period from 2026-06-01 to 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/RevenueFromContractWithCustomerExcludingAssessedTax","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-113"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/OperatingIncomeLoss","change":7.121912786562346,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Operating income","label_en":"Operating income","label_ko":"\uc601\uc5c5\uc774\uc775","period_type":"duration","xbrl_tag":"OperatingIncomeLoss"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/OperatingIncomeLoss","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-08-31","period_start":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-129","unit":"USD","value":559451000.0,"xbrl_fact_id":"f-129"},{"comparative":true,"instant":false,"period_end":"2025-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-130","unit":"USD","value":-91385000.0,"xbrl_fact_id":"f-130"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Operating income of USD 559,451,000 for the period from 2026-06-01 to 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/OperatingIncomeLoss","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-129"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/NetIncomeLoss","change":7.361960634567987,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Net income","label_en":"Net income","label_ko":"\uc21c\uc774\uc775","period_type":"duration","xbrl_tag":"NetIncomeLoss"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/NetIncomeLoss","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-08-31","period_start":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-145","unit":"USD","value":549807000.0,"xbrl_fact_id":"f-145"},{"comparative":true,"instant":false,"period_end":"2025-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-146","unit":"USD","value":-86421000.0,"xbrl_fact_id":"f-146"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Net income of USD 549,807,000 for the period from 2026-06-01 to 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/NetIncomeLoss","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-145"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/IncomeTaxExpenseBenefit","change":null,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Income tax","label_en":"Income tax","label_ko":"\ubc95\uc778\uc138","period_type":"duration","xbrl_tag":"IncomeTaxExpenseBenefit"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/IncomeTaxExpenseBenefit","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-08-31","period_start":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-141","unit":"USD","value":13606000.0,"xbrl_fact_id":"f-141"},{"comparative":true,"instant":false,"period_end":"2025-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-142","unit":"USD","value":0.0,"xbrl_fact_id":"f-142"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Income tax of USD 13,606,000 for the period from 2026-06-01 to 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/IncomeTaxExpenseBenefit","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-141"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/ShareBasedCompensation","change":0.09314726964230063,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Stock-based compensation","label_en":"Stock-based compensation","label_ko":"\uc8fc\uc2dd\ubcf4\uc0c1","period_type":"duration","xbrl_tag":"ShareBasedCompensation"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/ShareBasedCompensation","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-08-31","period_start":"2025-12-01","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-313","unit":"USD","value":31569000.0,"xbrl_fact_id":"f-313"},{"comparative":true,"instant":false,"period_end":"2025-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-314","unit":"USD","value":28879000.0,"xbrl_fact_id":"f-314"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Stock-based compensation of USD 31,569,000 for the period from 2025-12-01 to 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/ShareBasedCompensation","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-313"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/NetCashProvidedByUsedInOperatingActivities","change":3.461799342630469,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Operating cash flow","label_en":"Operating cash flow","label_ko":"\uc601\uc5c5\ud65c\ub3d9 \ud604\uae08\ud750\ub984","period_type":"duration","xbrl_tag":"NetCashProvidedByUsedInOperatingActivities"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/NetCashProvidedByUsedInOperatingActivities","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-08-31","period_start":"2025-12-01","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-335","unit":"USD","value":447144000.0,"xbrl_fact_id":"f-335"},{"comparative":true,"instant":false,"period_end":"2025-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-336","unit":"USD","value":-181633000.0,"xbrl_fact_id":"f-336"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Operating cash flow of USD 447,144,000 for the period from 2025-12-01 to 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/NetCashProvidedByUsedInOperatingActivities","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-335"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/PaymentsToAcquirePropertyPlantAndEquipment","change":-0.507045428925713,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Capex","label_en":"Capex","label_ko":"\uc124\ube44\ud22c\uc790","period_type":"duration","xbrl_tag":"PaymentsToAcquirePropertyPlantAndEquipment"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/PaymentsToAcquirePropertyPlantAndEquipment","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-08-31","period_start":"2025-12-01","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-341","unit":"USD","value":4373000.0,"xbrl_fact_id":"f-341"},{"comparative":true,"instant":false,"period_end":"2025-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-342","unit":"USD","value":8871000.0,"xbrl_fact_id":"f-342"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Capex of USD 4,373,000 for the period from 2025-12-01 to 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/PaymentsToAcquirePropertyPlantAndEquipment","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-341"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/AccountsReceivableNetCurrent","change":null,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Accounts receivable","label_en":"Accounts receivable","label_ko":"\ub9e4\ucd9c\ucc44\uad8c","period_type":"instant","xbrl_tag":"AccountsReceivableNetCurrent"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/AccountsReceivableNetCurrent","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-35","unit":"USD","value":20000000.0,"xbrl_fact_id":"f-35"},{"comparative":true,"instant":true,"period_end":"2025-11-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-36","unit":"USD","value":0.0,"xbrl_fact_id":"f-36"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Accounts receivable of USD 20,000,000 as of 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/AccountsReceivableNetCurrent","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-35"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/ContractWithCustomerLiabilityCurrent","change":-0.5102389078498294,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Deferred revenue (current)","label_en":"Deferred revenue (current)","label_ko":"\uc774\uc5f0\uc218\uc775(\uc720\ub3d9)","period_type":"instant","xbrl_tag":"ContractWithCustomerLiabilityCurrent"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/ContractWithCustomerLiabilityCurrent","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-59","unit":"USD","value":8610000.0,"xbrl_fact_id":"f-59"},{"comparative":true,"instant":true,"period_end":"2025-11-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-60","unit":"USD","value":17580000.0,"xbrl_fact_id":"f-60"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Deferred revenue (current) of USD 8,610,000 as of 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/ContractWithCustomerLiabilityCurrent","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-59"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/CashAndCashEquivalentsAtCarryingValue","change":1.916431810819566,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Cash","label_en":"Cash","label_ko":"\ud604\uae08","period_type":"instant","xbrl_tag":"CashAndCashEquivalentsAtCarryingValue"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/CashAndCashEquivalentsAtCarryingValue","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-31","unit":"USD","value":720242000.0,"xbrl_fact_id":"f-31"},{"comparative":true,"instant":true,"period_end":"2025-11-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-32","unit":"USD","value":246960000.0,"xbrl_fact_id":"f-32"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Cash of USD 720,242,000 as of 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/CashAndCashEquivalentsAtCarryingValue","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-31"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/Assets","change":0.7370109062901902,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Total assets","label_en":"Total assets","label_ko":"\ucd1d\uc790\uc0b0","period_type":"instant","xbrl_tag":"Assets"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/Assets","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-51","unit":"USD","value":1195298000.0,"xbrl_fact_id":"f-51"},{"comparative":true,"instant":true,"period_end":"2025-11-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-52","unit":"USD","value":688135000.0,"xbrl_fact_id":"f-52"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Total assets of USD 1,195,298,000 as of 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/Assets","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-51"},{"accession":"0001549595-26-000049","article_url":"https://aiswingx.com/p/nrix-2026q3","attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001549595-26-000049/StockholdersEquity","change":1.4049827756211084,"cik":1549595,"company":"NURIX THERAPEUTICS, INC.","concept":{"label":"Total equity","label_en":"Total equity","label_ko":"\uc790\uae30\uc790\ubcf8","period_type":"instant","xbrl_tag":"StockholdersEquity"},"filed_at":"2026-10-13","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/0001549595-26-000049-index.htm","filing_url":"https://aiswingx.com/f/0001549595-26-000049","form":"10-Q","id":"0001549595-26-000049/StockholdersEquity","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-08-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-101","unit":"USD","value":968311000.0,"xbrl_fact_id":"f-101"},{"comparative":true,"instant":true,"period_end":"2026-05-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-285","unit":"USD","value":402627000.0,"xbrl_fact_id":"f-285"}],"statement":"NURIX THERAPEUTICS, INC. (NRIX) reported Total equity of USD 968,311,000 as of 2026-08-31 in its 10-Q (accession 0001549595-26-000049, filed 2026-10-13).","ticker":"NRIX","url":"https://aiswingx.com/n/0001549595-26-000049/StockholdersEquity","verify_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm#f-101"}],"limit":100,"note":"Inline XBRL facts as filed with the SEC, each with a permanent citation URL and a deep link to the figure in the filing document.","offset":0,"total":12}